LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article: Chemoprevention of melanoma: theoretical and practical considerations.

    Demierre, Marie F / Sondak, Vernon K

    Cancer control : journal of the Moffitt Cancer Center

    2005  Volume 12, Issue 4, Page(s) 219–222

    Abstract: Background: Chemoprevention refers to the use of agents to reverse, suppress, or prevent carcinogenic progression of cancer. The use of chemoprevention is an unexplored strategy in melanoma prevention.: Methods: A retrospective review of the ... ...

    Abstract Background: Chemoprevention refers to the use of agents to reverse, suppress, or prevent carcinogenic progression of cancer. The use of chemoprevention is an unexplored strategy in melanoma prevention.
    Methods: A retrospective review of the literature was undertaken regarding the important elements in evaluating chemoprevention as a strategy in melanoma.
    Results: Several considerations need to be addressed before a chemoprevention agent can be moved to a large randomized trial. Statins have both experimental and epidemiologic evidence to support their further development as candidate chemopreventive agents, but the evidence is insufficient to justify large-scale phase III studies. A strong scientific rationale, a systematic approach to chemoprevention agent development with rigorous chemoprevention designs, and careful selection of surrogate endpoint biomarkers are critical issues in developing a chemoprevention strategy.
    Conclusions: Addressing these relevant considerations will allow for the development of chemoprevention in melanoma.
    MeSH term(s) Chemoprevention/methods ; Humans ; Melanoma/prevention & control ; Skin Neoplasms/prevention & control
    Language English
    Publishing date 2005-10
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1328503-8
    ISSN 1526-2359 ; 1073-2748
    ISSN (online) 1526-2359
    ISSN 1073-2748
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4467: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Assessment of delayed reporting of mycosis fungoides and Sezary syndrome in the United States.

    Dores, Graça M / Curtis, Rochelle E / Anderson, William F / Demierre, Marie-France

    Archives of dermatology

    2008  Volume 144, Issue 3, Page(s) 413–414

    MeSH term(s) Data Collection/standards ; Humans ; Incidence ; Mycosis Fungoides/epidemiology ; Mycosis Fungoides/etiology ; Reproducibility of Results ; SEER Program/statistics & numerical data ; Sezary Syndrome/epidemiology ; Sezary Syndrome/etiology ; Time Factors ; United States/epidemiology
    Language English
    Publishing date 2008-03
    Publishing country United States
    Document type Comment ; Letter
    ZDB-ID 212139-6
    ISSN 1538-3652 ; 0003-987X
    ISSN (online) 1538-3652
    ISSN 0003-987X
    DOI 10.1001/archderm.144.3.413
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.32: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.

    Foss, Francine / Demierre, Marie France / DiVenuti, Gina

    Blood

    2005  Volume 106, Issue 2, Page(s) 454–457

    Abstract: Denileukin diftitox, a genetically engineered fusion protein combining the enzymatically active domains of diphtheria toxin and the full-length sequence for interleukin-2 (IL-2), efficiently targets lymphoma cells expressing the high-affinity IL-2 ... ...

    Abstract Denileukin diftitox, a genetically engineered fusion protein combining the enzymatically active domains of diphtheria toxin and the full-length sequence for interleukin-2 (IL-2), efficiently targets lymphoma cells expressing the high-affinity IL-2 receptor (IL-2R) consisting of the alpha/p55/CD25, beta/p75/CD122, and gamma/p64/CD132 chains. In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, bexarotene, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox. To determine whether this biomodulatory effect could be recapitulated in vivo, we treated 14 patients with relapsed or refractory cutaneous T-cell lymphoma with escalating doses of bexarotene (75 mg/day-300 mg/day) and denileukin diftitox (18 mcg/kg per day x 3 days every 21 days) in a phase 1 trial. Overall response was 67% (4 complete responses, 4 partial responses). Modulation of IL-2R expression was observed at or above a bexarotene dose of 150 mg/day. Four patients experienced grade 2 or 3 leukopenia, and 2 had grade 4 lymphopenia. Our results demonstrate that the combination of denileukin diftitox and bexarotene is well tolerated and that even low doses (150 mg/day) of bexarotene are capable of in vivo upregulation of CD25 expression on circulating leukemia cells.
    MeSH term(s) Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bexarotene ; Diphtheria Toxin/administration & dosage ; Diphtheria Toxin/adverse effects ; Drug Tolerance ; Female ; Humans ; Interleukin-2/administration & dosage ; Interleukin-2/adverse effects ; Lymphoma, T-Cell, Cutaneous/drug therapy ; Lymphoma, T-Cell, Cutaneous/immunology ; Male ; Middle Aged ; Receptors, Interleukin-2/metabolism ; Recombinant Fusion Proteins/administration & dosage ; Recombinant Fusion Proteins/adverse effects ; Recurrence ; Skin Neoplasms/drug therapy ; Skin Neoplasms/immunology ; Tetrahydronaphthalenes/administration & dosage ; Tetrahydronaphthalenes/adverse effects ; Up-Regulation/drug effects
    Chemical Substances Diphtheria Toxin ; Interleukin-2 ; Receptors, Interleukin-2 ; Recombinant Fusion Proteins ; Tetrahydronaphthalenes ; denileukin diftitox (25E79B5CTM) ; Bexarotene (A61RXM4375)
    Language English
    Publishing date 2005-04-05
    Publishing country United States
    Document type Clinical Trial ; Clinical Trial, Phase I ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2004-11-4570
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Well-differentiated angiosarcoma of the scalp: an unusual clinical presentation.

    Chapas, Anne M / Askarian, Farhad / Demierre, Marie-France / Stefanato, Catherine M

    Journal of the American Academy of Dermatology

    2005  Volume 52, Issue 2 Suppl 1, Page(s) 58–59

    MeSH term(s) Aged ; Aged, 80 and over ; Craniocerebral Trauma/surgery ; Craniotomy/adverse effects ; Fistula/complications ; Head and Neck Neoplasms/pathology ; Hemangiosarcoma/pathology ; Hematoma, Subdural/surgery ; Humans ; Male ; Scalp/pathology ; Seroma/complications ; Skin Neoplasms/pathology
    Language English
    Publishing date 2005-02
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 603641-7
    ISSN 1097-6787 ; 0190-9622
    ISSN (online) 1097-6787
    ISSN 0190-9622
    DOI 10.1016/j.jaad.2004.05.027
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1540: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: DNA-ploidy in advanced gastric carcinoma is less heterogeneous than in early gastric cancer.

    Osterheld, Maria-Chiara / Caron, Liette / Demierre, Mireille / Laurini, Ricardo / Bosman, F T

    Cellular oncology : the official journal of the International Society for Cellular Oncology

    2004  Volume 26, Issue 1-2, Page(s) 21–29

    Abstract: This analysis of DNA-ploidy heterogeneity in advanced gastric carcinomas is consistent with the hypothesis of the emergence of a single aneuploid cell clone as a crucial mechanism in the progression from early gastric carcinoma to advanced gastric cancer. ...

    Abstract This analysis of DNA-ploidy heterogeneity in advanced gastric carcinomas is consistent with the hypothesis of the emergence of a single aneuploid cell clone as a crucial mechanism in the progression from early gastric carcinoma to advanced gastric cancer. The prognostic value of DNA-ploidy in gastric cancers has been a matter of controversy. Tumour DNA-ploidy heterogeneity, the presence within the same tumour of multiple stemlines differing in DNA content, has been described in various tumours including gastric cancers. The occurrence of such heterogeneity has been accepted as an explanation for the divergent DNA-ploidy results in this type of tumours. A previous study of early gastric cancers suggested that in pure diploid superficial carcinomas, genetic instability might lead to a cell clone which has undergone a ploidy shift and is more aggressive. If so, this would initially result in DNA-ploidy heterogeneity. Proliferative dominance of the aneuploid clone could eventually evolve to a homogeneous aneuploid tumour. In order to test this hypothesis, we studied DNA-aneuploidy and DNA-ploidy heterogeneity in advanced gastric carcinomas. We performed DNA cytophotometry on multiple samples collected from 16 advanced gastric carcinomas and found 15 DNA-aneuploid tumours (94%) and one diploid tumour. Multiple DNA-stemlines were found in 4 cases (26%). Analysis of proliferative activity performed on the same samples revealed higher proliferation rate in DNA-ploidy homogeneous tumours than in aneuploid heterogeneous tumours. Heterogeneous tumours did not overexpress p53. These results confirm that DNA-aneuploidy is frequent in advanced gastric cancer and demonstrate that a majority of these aneuploid tumours are not DNA-ploidy heterogeneous. Furthermore, the higher proliferative activity in homogeneous-aneuploid carcinomas and their more frequent overexpression of p53 support the hypothesis that in gastric cancer tumour progression implies the development of a dominant and more aggressive (higher proliferative activity, p53 overexpression) aneuploid cell clone.
    MeSH term(s) Aged ; Aneuploidy ; Carcinoma/genetics ; Carcinoma/pathology ; Cell Lineage/genetics ; Cell Proliferation ; Cell Transformation, Neoplastic/genetics ; DNA/genetics ; Diploidy ; Disease Progression ; Female ; Gene Expression Regulation, Neoplastic/genetics ; Humans ; Male ; Mutation/genetics ; Neoplasm Invasiveness/genetics ; Neoplasm Invasiveness/pathology ; Ploidies ; Stem Cells/physiology ; Stomach Neoplasms/genetics ; Stomach Neoplasms/pathology ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism
    Chemical Substances Tumor Suppressor Protein p53 ; DNA (9007-49-2)
    Language English
    Publishing date 2004-09-09
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2157351-7
    ISSN 1875-8606 ; 1570-5870
    ISSN (online) 1875-8606
    ISSN 1570-5870
    DOI 10.1155/2004/219293
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3139: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).

    Olsen, Elise A / Rook, Alain H / Zic, John / Kim, Youn / Porcu, Pierluigi / Querfeld, Christiane / Wood, Gary / Demierre, Marie-France / Pittelkow, Mark / Wilson, Lynn D / Pinter-Brown, Lauren / Advani, Ranjana / Parker, Sareeta / Kim, Ellen J / Junkins-Hopkins, Jacqueline M / Foss, Francine / Cacchio, Patrick / Duvic, Madeleine

    Journal of the American Academy of Dermatology

    2011  Volume 64, Issue 2, Page(s) 352–404

    Abstract: Sézary syndrome (SS) has a poor prognosis and few guidelines for optimizing therapy. The US Cutaneous Lymphoma Consortium, to improve clinical care of patients with SS and encourage controlled clinical trials of promising treatments, undertook a review ... ...

    Abstract Sézary syndrome (SS) has a poor prognosis and few guidelines for optimizing therapy. The US Cutaneous Lymphoma Consortium, to improve clinical care of patients with SS and encourage controlled clinical trials of promising treatments, undertook a review of the published literature on therapeutic options for SS. An overview of the immunopathogenesis and standardized review of potential current treatment options for SS including metabolism, mechanism of action, overall efficacy in mycosis fungoides and SS, and common or concerning adverse effects is first discussed. The specific efficacy of each treatment for SS, both as monotherapy and combination therapy, is then reported using standardized criteria for both SS and response to therapy with the type of study defined by a modification of the US Preventive Services guidelines for evidence-based medicine. Finally, guidelines for the treatment of SS and suggestions for adjuvant treatment are noted.
    MeSH term(s) Alkylating Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/therapeutic use ; Clinical Trials as Topic ; Combined Modality Therapy ; Drug Therapy, Combination ; Evidence-Based Medicine ; Histone Deacetylase Inhibitors/therapeutic use ; Humans ; Immunologic Factors/therapeutic use ; Methotrexate/therapeutic use ; Mycosis Fungoides/pathology ; Mycosis Fungoides/therapy ; Quality of Life ; Retinoids/therapeutic use ; Sezary Syndrome/immunology ; Sezary Syndrome/pathology ; Sezary Syndrome/therapy ; Skin Neoplasms/immunology ; Skin Neoplasms/pathology ; Skin Neoplasms/therapy
    Chemical Substances Alkylating Agents ; Antibodies, Monoclonal ; Antineoplastic Agents ; Histone Deacetylase Inhibitors ; Immunologic Factors ; Retinoids ; Methotrexate (YL5FZ2Y5U1)
    Language English
    Publishing date 2011-02
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 603641-7
    ISSN 1097-6787 ; 0190-9622
    ISSN (online) 1097-6787
    ISSN 0190-9622
    DOI 10.1016/j.jaad.2010.08.037
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1540: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Selection criteria for genetic assessment of patients with familial melanoma.

    Leachman, Sancy A / Carucci, John / Kohlmann, Wendy / Banks, Kimberly C / Asgari, Maryam M / Bergman, Wilma / Bianchi-Scarrà, Giovanna / Brentnall, Teresa / Bressac-de Paillerets, Brigitte / Bruno, William / Curiel-Lewandrowski, Clara / de Snoo, Femke A / Debniak, Tadeusz / Demierre, Marie-France / Elder, David / Goldstein, Alisa M / Grant-Kels, Jane / Halpern, Allan C / Ingvar, Christian /
    Kefford, Richard F / Lang, Julie / MacKie, Rona M / Mann, Graham J / Mueller, Kurt / Newton-Bishop, Julia / Olsson, Håkan / Petersen, Gloria M / Puig, Susana / Rigel, Darrell / Swetter, Susan M / Tucker, Margaret A / Yakobson, Emanuel / Zitelli, John A / Tsao, Hensin

    Journal of the American Academy of Dermatology

    2009  Volume 61, Issue 4, Page(s) 677.e1–14

    Abstract: Approximately 5% to 10% of melanoma may be hereditary in nature, and about 2% of melanoma can be specifically attributed to pathogenic germline mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A). To appropriately identify the small proportion of ... ...

    Abstract Approximately 5% to 10% of melanoma may be hereditary in nature, and about 2% of melanoma can be specifically attributed to pathogenic germline mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A). To appropriately identify the small proportion of patients who benefit most from referral to a genetics specialist for consideration of genetic testing for CDKN2A, we have reviewed available published studies of CDKN2A mutation analysis in cohorts with invasive, cutaneous melanoma and found variability in the rate of CDKN2A mutations based on geography, ethnicity, and the type of study and eligibility criteria used. Except in regions of high melanoma incidence, such as Australia, we found higher rates of CDKN2A positivity in individuals with 3 or more primary invasive melanomas and/or families with at least one invasive melanoma and two or more other diagnoses of invasive melanoma and/or pancreatic cancer among first- or second-degree relatives on the same side of the family. The work summarized in this review should help identify individuals who are appropriate candidates for referral for genetic consultation and possible testing.
    MeSH term(s) Genetic Counseling ; Genetic Testing ; Humans ; Melanoma/genetics ; Patient Selection ; Skin Neoplasms/genetics
    Language English
    Publishing date 2009-09-13
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, N.I.H., Intramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 603641-7
    ISSN 1097-6787 ; 0190-9622
    ISSN (online) 1097-6787
    ISSN 0190-9622
    DOI 10.1016/j.jaad.2009.03.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1540: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top